OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 apr 2011 - 07:26
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces agreement with top-10 biopharmaceutical company for development of a controlled release formulation
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces today that it has signed a feasibility agreement with a top-10 biopharmaceutical company to develop a controlled release formulation.
Under the contract announced today, OctoPlus will develop a controlled release formulation of an undisclosed peptide compound. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement. Financial terms of the current agreement are not disclosed.
Datum laatste update: 23 december 2025